Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at its site in Durham, North Carolina. The $1 billion expansion is a big step ...

A human papillomavirus (HPV) vaccine will be manufactured there, according to Merck's website. "Expanding our state-of-the-art manufacturing facility in Durham marks a significant milestone in our ...